(Fort Worth, TX, USA) — HEALTHPOINT, Ltd., a Texas-based market leader in tissue management, dermatology, and surgical products, has signed a distribution agreement for Mexico City-based TH Medical to market HEALTHPOINT’s Trizenol product line as well as the patented wound matrix product, OASIS®, in Mexico.

        This is HEALTHPOINT’s first distribution agreement in Mexico.

        “TH Medical is very pleased to be HEALTHPOINT’s partner in Mexico,” said Hugo Monroy-Sanchez, CEO, TH Medical. “We believe there is significant market opportunity for innovative products such as the wound matrix as an effective and safe alternative in advanced wound management.”

        “We believe there is also significant market opportunity for innovative skin asepsis products that help reduce hospital infections,” added Tere Ponce, Project Development and Training Manager, TH Medical.

        “This agreement establishes a firm foundation for HEALTHPOINT to extend its patented wound matrix technology and its innovative skin asepsis technology while providing a platform for future growth in Mexico,” said Jay Nisbet, Senior Director of International Business Development for HEALTHPOINT. Benjamin Vicuña, Director of International Business Development, will work with Mr. Nisbet to explore growth opportunities.

        HEALTHPOINT’s Trizenol^TM technology, a fast-acting and persistent topical antiseptic, is the first introduced in the field of surgical skin asepsis since the introduction of chlorhexidine gluconate in the 1970s. Chlorhexidine gluconate was heretofore recognized as the leading active for surgical scrubs and patient preparation for surgery.

        Trizenol’s name is derived from its three key elements: an alcohol active, an emollient for the skin, and a preservative – zinc pythrione.

        HEALTHPOINT’s TRISEPTIN®, the brush-free scrub^TM, contains Trizenol technology.

        “TRISEPTIN raises the standard of care for surgical scrubbing,” said H. Paul Dorman, HEALTHPOINT Chairman and CEO. “We are delighted to have T.H. Medical as our partner to take this technology into this extensive market.”

        HEALTHPOINT says that its patented formulation provides performance characteristics beyond chlorhexidine gluconate (4% CHG) and iodophor (7.5%PVP-I), the two traditional surgical scrub formulations used in hospitals across the U.S.

        HEALTHPOINT signed an exclusive, worldwide agreement for OASIS with Indiana-based COOK Biotech Inc., a leading manufacturer of tissue-engineered biomaterials for numerous medical and surgical applications, early last year and initially marketed OASIS in the U.S. Marketing efforts were extended to Canada late last year. Discussions for the marketing of OASIS in other international markets are currently in process.

        COOK Biotech will continue to manufacture OASIS.

        Based on COOK’s breakthrough Small Intestinal Submucosa, or SIS technology, OASIS is a natural, extracellular matrix, a new biomaterial which provides a supportive environment that allows a patient’s body to rebuild and repair damaged tissue.

        “OASIS is an intact, organic, biologically-derived matrix that is readily accepted by the body’s immunologic system without the rejection sometimes demonstrated by other reconstituted collagen dressings,” explained Dwayne Dixon, Group Marketing Director, Wound Preparation and Healing for HEALTHPOINT.

        OASIS can be used in the management of partial and full-thickness skin loss injuries, such as pressure, venous, and chronic vascular ulcers; diabetic ulcers; surgical and trauma wounds; second degree burns; abrasions; and, autograft donor sites.

        Since its inception in 1992, HEALTHPOINT Ltd., a DFB Pharmaceuticals, Inc. affiliate company, has established a strong domestic US presence in the research, development, and marketing of branded pharmaceuticals, over the counter drugs, and medical devices for tissue management, dermatology, and surgical. The company's aggressive research and development efforts have taken unique technologies to the market, setting the pace for a highly trained field sales organization that is expanding across North America and beyond.

        DFB, through its affiliate companies, contract partners, and branded marketing organizations, provides technology-driven products, outsourcing services, and licensing opportunities for the healthcare industry worldwide.

        HEALTHPOINT is based in Fort Worth, Texas, with additional offices in Canada. Visit HEALTHPOINT’s web site at www.healthpoint.com.

        COOK Biotech Incorporated, located in West Lafayette, Indiana, was established in 1995 to research, develop, and manufacture products based on extracellular matrix (ECM) Technology. COOK Biotech is actively developing ECM and scaffold-based biomaterials for numerous medical purposes. Medical products utilizing COOK’s patented ECM Technology are currently marketed worldwide for use in wound management and surgical repair of soft tissue. Together with a network of medical practitioners, COOK Biotech is identifying the medical needs most compatible with ECM technology and developing products to meet these needs.

###